Epigenetic regulation of protein phosphatase 2A (PP2A), Lymphotactin (XCL1) and estrogen receptor alpha (ER) expression in human breast cancer cells

Absence of the estrogen receptor alpha (ER) in human breast cancer cells is an indicator of poor prognosis, and predictive of lack of response to hormonal therapy. Previous studies in our laboratory and others have shown that epigenetic regulation, including DNA methylation and histone deacetylation, are common mechanisms leading to ER gene silencing. Through the use of pharmacologic inhibitors, 5-aza 2’deoxycytidine (AZA) and Trichostatin A (TSA), we have shown that alterations in both of these mechanisms results in synergistic re-expression of ER mRNA and functional protein. These alterations may play a larger role in stimulation of cell signaling pathways leading to ER expression. We have utilized newly developed genome wide screening microarray techniques to identify gene(s) contributing to the hormone independent phenotype and AZA/TSA mediated ER expression. From this screen, we identified and confirmed expression of 4 candidate genes (PP2A, XCL1, THY1 and NBC4) as potential regulators of the hormone independent phenotype. Expression of two genes, XCL1 and PP2A, appeared to be correlated with ER expression. PP2A expression was not changed with ER degradation using ICI 182,780 whereas XCL1 expression decreased in the presence of AZA/TSA and ICI 182,780. This suggests that PP2A may be a determinant of ER expression while XCL1 appears to be ER responsive and downstream of ER expression. These gene products may be novel targets to be further explored in the development of new therapeutics for ER negative breast cancer.

[1]  S. Pavey,et al.  Expression profiling reveals that methylation of TIMP3 is involved in uveal melanoma development. , 2004, International journal of cancer.

[2]  S. Weitzman,et al.  Hypermethylation of a Small CpGuanine-Rich Region Correlates with Loss of Activator Protein-2α Expression during Progression of Breast Cancer , 2004, Cancer Research.

[3]  Dipali Sharma,et al.  A Novel Histone Deacetylase Inhibitor, Scriptaid, Enhances Expression of Functional Estrogen Receptor α (ER) in ER negative human breast cancer cells in combination with 5-aza 2′-deoxycytidine , 2003, Breast Cancer Research and Treatment.

[4]  Tim Hui-Ming Huang,et al.  Differential distribution of DNA methylation within the RASSF1A CpG island in breast cancer. , 2003, Cancer research.

[5]  P. Keng,et al.  THY1 expression is associated with tumor suppression of human ovarian cancer. , 2003, Cancer genetics and cytogenetics.

[6]  Tim Hui-Ming Huang,et al.  Triple analysis of the cancer epigenome: an integrated microarray system for assessing gene expression, DNA methylation, and histone acetylation. , 2003, Cancer research.

[7]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[8]  A. Davidoff,et al.  Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. , 2003, Blood.

[9]  N. Davidson,et al.  The biology of breast carcinoma , 2003, Cancer.

[10]  Long-Cheng Li,et al.  MethPrimer: designing primers for methylation PCRs , 2002, Bioinform..

[11]  H. Yao,et al.  Adenovirus-mediated intratumoral lymphotactin gene transfer potentiates the antibody-targeted superantigen therapy of cancer , 2002, Journal of Molecular Medicine.

[12]  Tim Hui-Ming Huang,et al.  Expressed CpG island sequence tag microarray for dual screening of DNA hypermethylation and gene silencing in cancer cells. , 2002, Cancer research.

[13]  R. Pili,et al.  Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer. , 2002, Cancer research.

[14]  H. Hamada,et al.  Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100 , 2002, Gene Therapy.

[15]  A. Bird.  Methylation Talk Between Histones and DNA , 2001, Science.

[16]  J. Herman,et al.  Synergistic activation of functional estrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells , 2001 .

[17]  D. McDonnell,et al.  The Human Estrogen Receptor-α Is a Ubiquitinated Protein Whose Stability Is Affected Differentially by Agonists, Antagonists, and Selective Estrogen Receptor Modulators* , 2001, The Journal of Biological Chemistry.

[18]  J. Barrett,et al.  Suppression of tumorigenicity in human ovarian carcinoma cell line SKOV-3 by microcell-mediated transfer of chromosome 11. , 2001, Cancer genetics and cytogenetics.

[19]  C. Allis,et al.  Translating the Histone Code , 2001, Science.

[20]  J. Herman,et al.  Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. , 2000, Cancer research.

[21]  S. Zołnierowicz.  Type 2A protein phosphatase, the complex regulator of numerous signaling pathways. , 2000, Biochemical pharmacology.

[22]  C. Allis,et al.  Acetylation and chromosomal functions. , 2000, Current opinion in cell biology.

[23]  A. Bird,et al.  Methylation-Induced Repression— Belts, Braces, and Chromatin , 1999, Cell.

[24]  R. Clarke,et al.  Differential distribution of protein phosphatase 2A in human breast carcinoma cell lines and its relation to estrogen receptor status. , 1999, Cancer letters.

[25]  A. Razin,et al.  CpG methylation, chromatin structure and gene silencing—a three‐way connection , 1998, The EMBO journal.

[26]  Colin A. Johnson,et al.  Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex , 1998, Nature.

[27]  S. Baylin,et al.  Role of Estrogen Receptor Gene Demethylation and DNA Methyltransferase·DNA Adduct Formation in 5-Aza-2′deoxycytidine-induced Cytotoxicity In Human Breast Cancer Cells* , 1997, The Journal of Biological Chemistry.

[28]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[29]  S. Weitzman,et al.  Methylation of estrogen and progesterone receptor gene 5' CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  S. Baylin,et al.  Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. , 1995, Cancer research.

[31]  S. Baylin,et al.  Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. , 1994, Cancer research.

[32]  Alan P. Wolffe,et al.  A positive role for histone acetylation in transcription factor access to nucleosomal DNA , 1993, Cell.

[33]  A. Bird.  CpG-rich islands and the function of DNA methylation , 1986, Nature.

[34]  Matty P. Weijenberg,et al.  A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer , 2002, Nature Genetics.

[35]  T. Bestor,et al.  DNA methyltransferases. , 1994, Current opinion in cell biology.

[36]  T. Bestor,et al.  Cloning of a mammalian DNA methyltransferase. , 1988, Gene.